RE:RE:RE:RE:RE:RE:The market is boredI think a few of the upcoming events I listed previously would work. If, instead of just allowing the 30-days to pass without objection, the FDA formally/expressly approves the company's IND application, which they can do at their discretion, that news should make for a nice pop.
A licensing deal in one of the RoW countries for OPX, depending on dollar value should work too. Sale of Citagenix as well. The combination of multiple positive events and some media attention wouldn't hurt either.
woundedknee wrote:
Based on these timelines i would say that the market will continue to be "bored". Can anyone think of any, (and I restate the word "any") events in the short or medium term that would push the sp up to the 50 to 60 cent mark that was mentioned in a previous post? Of course, not withstanding a consolidation. Does this company, right now, have enough going for it to be bought out before phase111 trials, or even before a RS. And does Antibe move to the Nasdaq before phase111? I believe Dan suggested as much. Although I could be wrong.